Differential induction of cell death in mycobacteria-infected monocytes and macrophages has been invoked as one possible mechanism by which some tumor necrosis factor (TNF)-targeted biologicals reactivate tuberculosis more frequently than others. We infected primary human monocytes and monocyte-derived macrophages with the virulent Mycobacterium tuberculosis strain H37Rv and followed the rate of cell death in the absence or presence of a wide concentration range of four different TNF-targeted biologicals: infliximab and adalimumab (both monoclonal antibodies to human TNF) and etanercept and polyethylene-glycols TNFR1 (fusion constructs of human TNFR2 and TNFR1, respectively). None of the TNF-targeted biologicals used modulated the death rate of monocytes/macrophages induced by infection with M. tuberculosis alone. Our data support the view that mycobacteria-induced cell death is largely independent of TNF and that the primary target for differential modulation by TNF-targeted biologicals during tuberculosis is not a recently recruited monocyte or freshly differentiated macrophage.
INTRODUCTION
The increased clinical use of tumor necrosis factor (TNF) antagonists has been accompanied by increased reporting of granulomatous infectious diseases, including tuberculosis (TB), histoplasmosis, and other less common conditions (Weisman 2002; Fleischmann 2003) . Clinical reports of granulomatous infections indicate a greater incidence of reactivation TB with infliximab and adalimumab, both anti-TNF antibodies, than by etanercept, a soluble TNFR2 fusion construct (Fleischmann et al., 2002; Gardam et al., 2003; Wallis et al., 2004; Keystone, 2005) . This is consistent with the apparent differential therapeutic activities of these two classes of drugs for granulomatous inflammatory conditions, such as Crohn's disease (Sandborn et al., 2001; Lamprecht et al., 2002; Sandborn and Hanauer, 2002; Serio, 2003; Utz et al., 2003) . Despite the capacity of both classes of drugs to neutralize TNF function, the drugs' respective modes of action in vivo may therefore differ considerably from each other. Three hypotheses were discussed that might explain the more frequent reactivation of latent Mycobacterium tuberculosis infection by TNF-targeted mAbs than by the soluble TNF receptor fusion construct: (i) differential net blockade of TNF bioactivity; (ii) differential inhibition of TNF signaling; or (iii) differential induction of target cell death, that is, differential disruption of macrophage and, consequently, granuloma integrity (Ehlers, 2005) .
With regards to the third hypothesis, TNF-neutralizing antibodies have been shown to induce apoptosis both in vitro and in vivo, whereas no such results have been reported with etanercept. Specifically, infliximab caused apoptosis in monocytes from patients with Crohn's disease through a caspase 3-dependent pathway, and ex vivo studies in patients treated with infliximab showed a significant increase in apoptotic CD3 þ lymphocytes in the lamina propria of colonic biopsies (Lugering et al., 2001 ; Van den Brande et al., 2003) . Analyses of tissue biopsies in M. tuberculosis-infected mice following antibody-mediated inhibition of TNF activity also indicated increased apoptotic activity within granulomatous lesions (Mohan et al., 2001) , whereas in patients treated with infliximab, apoptosis within pulmonary granulomas was apparently decreased (Keane et al., 2001) , leaving this issue unresolved. Thus far, there has been no experi-mental study directly documenting the consequence of TNFtargeted biologicals on M. tuberculosis-infected monocytes and macrophages with respect to differential induction of apoptosis.
It is also possible that infliximab -having bound to membrane-associated TNF on monocytes or lymphocytesactivates complement or causes antibody-dependent cellular cytotoxicity via its Fc tail (Scallon et al., 1995) . This would help explain the relatively heightened (albeit still rare) occurrence of disseminated TB in infliximab-treated patients, because the lysed granuloma macrophages would spill M. tuberculosis organism into the bloodstream. However, extrapulmonary M. tuberculosis has also been documented in patients treated with etanercept (Gardam et al., 2003; Mohan et al., 2004) . To date, no studies have addressed directly the issue of whether the different TNF-targeted biologicals differentially induce the lysis of M. tuberculosis-infected macrophages.
In this study, it was our goal to determine whether treatment with TNF-targeted biologicals (infliximab, adalimumab, etanercept, and a novel experimental soluble TNFR1 construct with a polyethylene-glycol (PEG) modification) modulate the death of M. tuberculosis-infected primary human monocytes and macrophages. Our data indicate that mycobacteria-induced target cell death proceeds, to a large extent, independently of TNF.
RESULTS

Mycobacteria induce cell death in human primary monocytes
Mycobacteria have been shown to induce cell death in a variety of cellular systems. The underlying mechanisms include induction of apoptosis as well as necrosis (Keane et al., 1997; Park et al., 2006) . In initial infection experiments using human primary monocytes as well as macrophages, we observed activation of caspase 3 as well as the release of lactate dehydrogenase indicating that, indeed, both apoptotic and necrotic pathways are involved. To monitor comprehensively the influence of TNF-targeted biologicals on M. aviumand M. tuberculosis-induced overall cell death, we established a FACS-based quantitative method using the DNA dye TO-PRO-3 as indicator of cell death (Van Hooijdonk et al., 1994) . This assay gives a very reliable read-out of overall death events (both, apoptotic and necrotic) in the culture system: cells binding TO-PRO-3 are scored as dead, whereas cells negative for TO-PRO-3 staining are viable. Figure 1 demonstrates that the majority of highly purified human monocytes remain TO-PRO-3 negative 24 hours after infection with M. tuberculosis. This changes dramatically after 48 hours, at which time point cells significantly decrease in size. At 72 hours after placement in culture, almost all cells are TO-PRO-3 positive, indicating cell death.
We then performed infection experiments using an increasing multiplicity of infection (MOI) of 1:1, 3:1, and 10:1 M. tuberculosis and monitored cell death at different time points after infection (24-72 hours). Figure 2 shows that the induction of monocyte death induced by M. tuberculosis, as measured by TO-PRO-3, is time and dose dependent. Similar results were obtained when human monocyte-derived macrophages were used. For subsequent experiments shown, a MOI of 1:1 (M. tuberculosis) was used and flow cytometric analysis was performed at 48 hours after infection.
Supernatants collected from mycobacteria-infected monocytes were added to L929 murine fibroblasts to measure their cytotoxic potential. In repeated experiments, these supernatants induced cell death in approximately 90% of the fibroblasts (data not shown), whereas the addition of mycobacteria alone did not have this effect. Analysis of TNF contents in these supernatants by ELISA (R&D Systems, Wiesbaden, Germany) showed the presence of 0.2-5 ng/ml depending on the dose used and the time point at which the cells were analyzed (data not shown). This indicated that cell death in monocytes induced by M. tuberculosis infection might be a consequence of TNF.
All TNF-targeted biologicals used efficiently block the cytotoxic effect of TNF Based on these observations, we added 5 ng/ml human TNF on L929 cells in the absence or presence of increasing concentrations of four different TNF-targeted biologicals (etanercept, PEGsTNFR1, adalimumab, and infliximab) . Figure 3 shows that all four reagents used blocked the TNFmediated cytotoxicity efficiently. Concentrations around 1 mg/ml prevented the TNF-induced cell death almost completely. Figure 4 demonstrates that the presence of these very efficient blockers of TNF-mediated cytotoxicity ( Figure 3 ) did not influence the rate of cell death significantly, which remained in the range of 60% for monocytes (40% for macrophages, Figure 5 ) regardless of the dose of biological used. Some reduction in cell death was noted in monocyte cultures treated with PEGsTNFR1, but this was a somewhat inconsistent finding and was not dose dependent ( Figure 4c ). Macrophage death was increased slightly in the presence of high doses of etanercept, though this effect did not reach statistical significance ( Figure 5 ). Macrophage cell death was also increased slightly in the presence of adalimumab, but this effect was not dose dependent and also did not reach statistical significance ( Figure 5 ). In order to exclude potential adverse effects of the substances on the viability of human primary monocytes under the used conditions, we cultured the cells in the absence or presence of increasing concentrations of the four drugs and measured the amount of TO-PRO-3-positive cells after 48 hours. None of the TNF antagonists used had a significant, detrimental effect on cellular viability, even when used at concentrations of 100 mg/ml. Similar results were obtained with human monocyte-derived macrophages (data not shown).
The effect of human serum in this culture system was also analyzed. In the presence of 2-10% active, non-heatinactivated, pooled AB serum, neither infliximab, adalimumab, etanercept nor PEGsTNFR1 modulated the rate of lysis significantly (as determined by lactate dehydrogenase release; Takara lactate dehydrogenase Cytotoxicity Detection Kit, Mobitec, Gö ttingen Germany) in human monocytes or macrophages infected with M. tuberculosis, regardless of the dose of biological used (data not shown).
Primary human monocytes and macrophages are highly resistant to TNF-induced cell death in vitro
The fact that TNF-neutralizing reagents had no effect on mycobacteria-induced cell death suggested that monocytes and macrophages might be largely refractory to TNFmediated cytotoxicity. Indeed, when exposed to a wide concentration range of recombinant TNF, which covers the range of endogenously produced TNF release in culture (in the lower ng/ml range), myeloid cells -in stark contrast to fibroblasts -were resistant with regard to the induction of cell death ( Figure 6 ). In repeated experiments, a slightly protective role of TNF was even observed, in that TNF treatment resulted in extended survival of monocytes. Only at TNF concentrations approximately 200-to 1,000-fold higher than endogenously produced TNF levels was a measurable increase in monocyte cell death observed. The same type of experiment was performed with human monocyte-derived macrophages giving identical results (data not shown).
DISCUSSION
We studied the role of TNF in mycobacteria-induced cell death in primary human monocytes and macrophages. None of the TNF-targeted biologicals tested (etanercept, PEGsTNFR1, adalimumab, and infliximab) modulated the rate of cell death induced by a virulent strain of M. tuberculosis (H37Rv). We interpret these findings as a strong indication that the cell death, which is induced in monocytes and macrophages following mycobacterial infection is TNF-independent predominantly. As a consequence, it appears unlikely that the different rates of reactivation TB in patients treated with different TNF-targeted biologicals can be attributed to a differential induction of monocyte or macrophage cell death by any of the biologicals investigated here.
TNF is a critical mediator in the activation of immune cells with regard to the antibacterial, the antiviral, as well as the antitumor response of the immune system. Depending on the cell type, TNF concentration may have protective as well as cytotoxic functions and is able to induce apoptotic as well as necrotic cell death (reviewed by Locksley et al., 2001; Wajant et al., 2003) . Whereas a variety of tumor cell lines and fibroblasts undergo apoptosis in response to TNF (Granger et al., 1969; Carswell et al., 1975; Fransen et al., 1986) , TNF has been shown to protect human primary monocytes from undergoing programmed cell death (Mangan et al., 1991) . Low concentrations of TNF have even been shown to enhance survival of human as well as murine primary monocytes and macrophages (Dü rrbaum-Landmann et al., 1996; Shi et al., 2003) . The results obtained in our study corroborate these findings. Human monocytes and macrophages were found to be 200-to 1,000-fold less sensitive to TNF-induced cytotoxicity than fibroblasts. The decision whether a cell is sensitive or refractory to TNFinduced cell death is likely to depend on a distinct TNF receptor 1 and -2 expression pattern on the cell surface as well as cell type-specific signaling events induced by these receptors (reviewed by Wajant et al., 2003) . This may in part explain the discrepant results obtained with mycobacteriainfected alveolar macrophages (Keane et al., 1997; Balcewicz-Sablinska et al., 1998; Fratazzi et al., 1999; Spira et al., 2003) . In these studies, human alveolar macrophages infected with M. tuberculosis were found to undergo programmed cell death, a virulent strain (H37Rv) inducing significantly less apoptosis than an avirulent strain (H37Ra). Along similar lines, Park et al. (2006) who compared a M. tuberculosis laboratory strain with several clinical isolates in a murine in vivo model, also showed that the clinical isolates led to an enhanced rate of cell death, which was reported to be owing mainly to necrotic processes. This inverse correlation of mycobacterial virulence and induction of cell death was attributed in part to the superior capacity of the virulent strain to induce the release of soluble TNFR2 into the supernatant, antagonizing the effect of TNF, at least in the in vitro system using alveolar macrophages (BalcewiczSablinska et al., 1998) . In addition, the virulent strain of M. tuberculosis was found to modulate the TNF-induced proapoptotic gene expression pattern in alveolar macrophages (Spira et al., 2003) . It is possible that cell death induced by virulent strains of M. tuberculosis is largely independent of TNF (as shown in our study), but that the high rates of cell death induced by less virulent mycobacterial strains may be predominantly TNF mediated. This would be consistent with the finding that less virulent mycobacterial strains induce significantly higher amounts of TNF than virulent strains (Reed et al., 2004; Blumenthal et al., 2005) .
In order to explain the reactivation of TB during treatment of patients with TNF antagonists, two mechanisms of target cell death have been discussed. One is based on the observation by Scallon et al. (1995) , that a cell expressing mTNF, for example, macrophages and T cells, may be lysed by the complement system after binding of anti-TNF antibody, as shown by the lysis of a constitutively mTNF expressing, transfected T-cell line after addition of the anti-TNF antibody cA2. In this study, however, we used highly purified human monocytes and macrophages and did not observe an enhanced complement-dependent lysis of the cells by all four TNF antagonists used. Also, the use of human serum instead of fetal calf serum had no effect on the rate of TO-PRO-3-positive, dead cells in our experiments.
The second hypothesis focused on cell death induced by reverse signaling in mTNF expressing immune cells after the binding of TNF antagonists, which in consequence would also lead to reduced TNF levels (Van den Brande et al., 2002 Brande et al., , 2003 . Watts et al. (1999) postulated this mechanism based on experiments obtained with a LPS-stimulated murine macrophage cell line (RAW264.7): binding of sTNF1 on mTNF in these cells led to a rise in intracellular calcium levels, which has been interpreted as TNF antagonist-induced signaling in mTNF-bearing cells. This effect has also been reported by Higuchi et al. (1997) , who showed that binding of anti-TNF antibodies to mTNF expressing virus infected T cells changed their capacity to stimulate IgM production of B cells, by inducing an enhanced calcium release as well as an enhanced IL-2 and IFN-g release.
As the generation of TNF includes the formation of mTNF before the cleavage by tumor necrosis factor-a-converting enzyme (Tang et al., 1996; Black et al., 1997) , it is highly likely that mTNF was present on the cell surface of monocytes and macrophages after mycobacterial stimulation in our assay system. As we did not observe an influence of the TNF antagonists on cell death in the absence or presence of mycobacteria, we conclude that primary human monocytes and macrophages may behave differently with regard to both complement-induced lysis or reverse signaling after binding of an anti-TNF antibody compared to transfected cell lines. However, further work is needed to quantitate the presence and define the role of mTNF expression in human primary myeloid cells.
In its strategy to fight successfully and eradicate a mycobacterial infection and to limit the dissemination of the pathogen, the immune system activates distinct cell populations (e.g. alveolar macrophages, CD4
þ -, CD8 þ -, gd-T cells, TH1 effector cells as well as natural killer cells) to produce critical mediators such as TNF, IL-12, and IFN-g. The interplay of these cellular as well as the soluble factors are important to initiate and control the migration of immune cells to the site of infection (reviewed by Algood et al., 2005; Ulrichs and Kaufmann, 2006 ). An essential player in the control of mycobacterial infections is TNF, as it is a key regulator of granuloma formation and maintenance at the infectious foci (reviewed by Ehlers, 2003; Algood et al., 2005) . Granulomas are highly dynamic and flexible multicellular compartments, whose integrity depends on finely balanced, tuned local cytokine and chemokine production (reviewed by Adams, 1976; Flynn and Chan, 2001; Ehlers and Hö lscher, 2006) to enable an effective antimycobacterial response, which does not lead to a severe damage of the surrounding healthy tissue. Following mycobacterial infections, TNF-and TNFR1 (p55) gene-deficient mice develop severe tissue damage, which is due to the lack of the regulation of the T-cell response by activation-induced TNFmediated cell death of these lymphocytes (Ehlers et al., 2000) .
Our in vitro study largely excludes the invading monocyte and recently differentiated macrophage as a prime target whose integrity may be modulated by TNF-targeted biologicals in the course of M. tuberculosis infection. It is still possible that resident tissue macrophages, or cells with a different distribution of TNF receptors, may be affected by these reagents, particularly following activation by mycobacterial infection. However, it appears more likely that other cells important in the regulation of the inflammatory response to M. tuberculosis, in particular T cells, may be more sensitive to local TNF levels and their neutralization and may even be differentially affected by different TNF-targeted biologicals, depending on the density of TNF receptors on their surface. Indeed, increased apoptosis of T cells following treatment of patients with monoclonal anti-TNF antibodies (infliximab and adalimumab), but not soluble receptor constructs (etanercept) was reported (Vigna-Perez et al., 2005; Sieper and Van Den, 2005) . If the loss or dysregulation of M. tuberculosis-specific T cells could be substantiated further in this process, this would readily explain the occurrence of reactivation TB.
MATERIALS AND METHODS
TNF antagonists
Etanercept (Enbrel s
) and PEGsTNFR1 (a soluble human TNFR1 construct with a PEG tail to increase its serum half-life) were provided by Amgen Inc (Thousand Oaks, CA). Adalimumab (Humira s ) was purchased from Abbott, Wiesbaden, Germany, and infliximab (Remicade s ) was obtained from Essex Pharma, Munich, Germany.
Bacteria
M. tuberculosis strain H37Rv was obtained from the Trudeau Institute (Saranac Lake, NY) and cultured in Middlebrook 7H9 medium supplemented with OADC (oleic acid, albumin dextrose, catalase; BD Biosciences, Heidelberg, Germany) to mid-logarithmic phase. Aliquots were frozen at À701C until needed. For stimulation experiments, strains were thawed at room temperature and spun down with 1000 Â g for 10 minutes to adjust for inoculum size.
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Bacteria were resuspended in phosphate-buffered saline and added to the cells for the times indicated.
Cell preparation and differentiation
Human primary monocytes and monocyte-derived macrophages were isolated and cultured as described previously (Reiling et al., 2001) . Experiments with human primary cells were approved by the regional Ethics Review Board. Cell viability before experiments was measured by trypan blue exclusion and was always greater than 95%.
Analysis of cell death by flow cytometry
Cells were stained with TO-PRO-3 Iodide (2 mM; Mobitec, Gö ttingen, Germany), which has been used in previous studies to determine apoptotic and necrotic cell death (Van Hooijdonk et al., 1994; Suzuki et al., 1997; Diaz-Romero et al., 2002) . Staurosporine (300 nM, Calbiochem, Darmstadt, Germany) was used as positive control (Bertrand et al., 1994) . Subsequently the cells were analyzed in a flow cytometer (FACS Calibur, BD Biosciences, Heidelberg, Germany) using the HeNe laser.
L929 cytotoxicity assay
TNF cytotoxicity was analyzed in a 20-hour cytotoxicity assay using L929 cells in the presence of 1.25 mg/ml actinomycin D. Cells were stained subsequently with crystal violet and absorbance was measured at 550 nm (Matthews and Neale, 1987) .
Statistical analysis
Data obtained from independent experiments are presented as means7SD, and were compared by the Wilcoxon test. Differences were considered significant for P-values o0.05.
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